Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
Status:
Completed
Trial end date:
2018-09-28
Target enrollment:
Participant gender:
Summary
A single oral dose of BMS-986177 administered to subjects of mild hepatic impairment,
moderate hepatic impairment and healthy matched subjects to evaluate pharmacokinetics,
safety, and tolerability in these subjects